Eli M. Wallace Receives Stock Award at BridgeBio Oncology Therapeutics Inc (BBOT) — SEC Form 4, Aug 28, 2025

SEC Form 4 · No Market Transaction

Stock Award

Compensation grant — no market purchase or sale.

Reporting Owner

Eli M. Wallace

CEO

TXN 2025-08-26 · FILED 2025-08-28

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

BridgeBio Oncology Therapeutics Inc

BBOT CIK 0001869105

Reporting Owner

Name	Relationship
Eli M. Wallace CIK 0001776352	Director CEO

Eli M. Wallace at BridgeBio Oncology Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at BridgeBio Oncology Therapeutics Inc

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F1	$9.59	2025-08-26	A - Award/Grant	499,731 A	$0.00	2035-08-25	499,731 Common Stock	Direct

Footnotes (1)

F1: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Show more

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BridgeBio Oncology Therapeutics Inc

GET /v1/forms/4/0000950170-25-111992 API docs